tbuckley/cabot-search huggingface dataset:
SAT0338 Tolerance and efficacy of a new formulation of diacerein: Results of a multicenter, randomized, double-blind, controlled trial in patients with knee osteoarthritis
Authors: X. Chevalier, P. Richette, F. Rannou, B. Avouac, M. Dapoigny, P. Ducrotte, D. Jean Louis, B. Savarieau, D. Blanc, M. Marty
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Diacerein [Symptomatic Slow-Acting Drugs in Osteoarthritis (SYSASOA)], has demonstrated its efficacy in patients with hip or knee osteoarthritis in several randomized placebo controlled clinical trials. The efficacy/safety balance of diacerein is hampered by occurrence of diarrhea. A bioequivalent new formulation of diacerein (ART GT) (44 mg) was developed in order to reduce diarrhea. <h3>Objectives</h3> To test the hypothesis of better gastrointestinal safety of a new diacerein formulation (ART GT) compared to the usual formulation (ART®50) in patients with knee osteoarthritis (KOA). <h3>Methods</h3> In a randomised double-blind controlled trial, patients with symptomatic KOA (baseline pain &gt;40 mm on a 0-100 mm visual analogue scale [VAS]) seen by office-based physicians in 2009-2010 were randomly assigned to either ART GT or ART®50 for 3 months (twice daily). The primary end point was the "diarrhea event" related to study drug (adjudicated by an independent committee) over the first four weeks of treatment. A "diarrhoea event" was defined as any of the following criteria: at least 3 stools daily for at least 3 consecutive days, diarrhoea hindering daily life for at least 5 days, diarrhoea of sufficient severity to require discontinuation of the study drugs, diarrhoea of sufficient severity to require the use of anti-diarrheic medications. Secondary endpoints included: pain [VAS]) WOMAC score, patient and investigator overall assessments, response to treatment following OMERACT/OARSI criteria, consumption of NSAIDs/analgesics, global safety over a three months. <h3>Results</h3> Of 547 randomised patients, 517 patients were included in the full analysis set. The proportion of patients experiencing at least 1 diarrhea event was significantly smaller in the ART GT group (30.5%) than in the ART®50 group (41.0%) (p=0.01). There were more patients who discontinued the study treatment for TEAE in the ART®50 group (23.5%) than in the ART GT group (15.0%) (p=0.012). Analyses of all efficacy endpoints showed no differences between the two groups: overall, mean decrease of pain of 24 mm and 56% responders on OARSI criteria. <h3>Conclusions</h3> The safety profile of ART GT was significantly better than that of ART®50 in regard to gastrointestinal disorders with the same level of efficacy. (ClinicalTrials.gov number 2009-009990-84). <h3>Disclosure of Interest</h3> X. Chevalier Consultant for: Negma, P. Richette Consultant for: Negma, F. Rannou Consultant for: Negma, B. Avouac Consultant for: Negma, M. Dapoigny Consultant for: Negma, P. Ducrotte Consultant for: Negma, D. Jean Louis Consultant for: Negma, B. Savarieau: None Declared, D. Blanc Employee of: Negma, M. Marty Consultant for: Negma
Serum Enzymes in Muscular Dystrophy and Certain Other Muscular and Neuromuscular Diseases
Authors: Carl M. Pearson
Journal: New England Journal of Medicine (1957)

THE enzyme glutamic oxalacetic transaminase is widely distributed in animal tissues and is found in greatest concentration in cardiac and skeletal muscle.1 In the normal animal this enzyme is almost exclusively confined within the body cells, and only a very small amount is present in the circulation. Destruction of tissue will apparently liberate some of the contained enzyme, which will appear in the serum. A transitory increase in the level of this enzyme is the basis for a reliable laboratory determination of acute myocardial injury.2 , 3 Necrosis of some other tissues, especially the liver, also may produce an increase in the . . .
AB0937 Intravenous Immunoglobulin (IVIG) is Effective and Safe in Severe or Refractory Rheumatic Diseases
Authors: R. Fonseca, D. Gonçalves, F. Aguiar, J. Abelha-Aleixo, P. Madureira, R. Vieira, A. Bernardo, M. Bernardes, E. Mariz, L. Costa
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Intravenous immunoglobulin (IVIG) is effective in a wide range of clinical conditions, other than primary immunodeficiency, including rheumatic diseases. In fact, in the era of newer immunosuppressive drugs, there has been an over-increasing number of clinical indications for which IVIG has been tried with success. <h3>Objectives</h3> To evaluate the effectiveness and adverse events of off-label IVIG treatment in different rheumatic diseases, in patients of our Rheumatology Department. <h3>Methods</h3> We performed an observational retrospective study. Patients treated with IVIG between 2007 and 2013 were included. Only off-label IVIG administrations were considered. <h3>Results</h3> 21 patients were included. 18 (85,7%) were female, mean age 50,5±14,3 years and mean disease duration 4±5,7 years. The patients received a median of 14,5 [1-48] courses/patient (total of 346 administrations). The mean follow-up for long-term therapy was 21,80±18 months. 19 patients received a high dose IVIG protocol (2g/kg divided in 4 days) monthly for 6 months, followed by therapy every 2–3 months. 2 SLE patients with haematological flare obtained rapid improvement with only one pulse of treatment. The diagnoses were: systemic lupus erythematosus (6), polymyositis (4), dermatomyositis (2) systemic sclerosis/polymyositis overlap syndrome (2), mixed connective tissue disease (1) and mononeuritis multiplex vasculitis (6; 2 secondary to parvovirus B19 infection, 1 cryoglobulinemic vasculitis, 1 rheumatoid vasculitis, 1 ANCA related vasculitis) and livedoid vasculopathy (1). The clinical indications for start IVIG were: disease severity (4), unresponse to other treatments (5) or contra-indications/adverse events with previous immunosuppressive drugs (12; 10 due to infections and 2 due to toxicity). No severe adverse events were reported during the follow-up. The response to IVIG treatment was remission in 18 patients. The patient with livedoid vasculopathy, despite the initial good improvement, lost treatment response after 7 years. 1 SLE patient with severe thrombocytopenia did not respond and was treated with rituximab. 1 patient with polymyositis did not respond to IVIG and his diagnosis is currently being reassessed. <h3>Conclusions</h3> In our experience, IVIG has shown efficacy in a wide range of rheumatic diseases, without occurrence of severe adverse events. IVIG is a good choice especially for patients with unresponsive, flare-up or severe disease. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.4592
Abstract LB-22: Repression of alpha-, beta- and gamma-catenin genes by SNAI2 in human breast cancer cells
Authors: Mukul K. Mittal, Smita Misra, Charvann K. Bailey, Gautam Chaudhuri
Journal: Cancer Research (2010)

Abstract SNAI2 is a transcriptional repressor protein implicated in the proliferation and metastasis of several human cancer cells. It binds to the E2-box sequence of its target gene promoters and down regulates their expressions by chromatin remodeling. While studying SNAI2-binding gene promoters in the human breast cells by ChIP-DSL technique, we found that SNAI2 binds to the promoters of the cytoskeleton proteins alpha-, beta- and gamma-catenins. These proteins help cells to maintain their epithelial phenotype and apico-basal polarity. Reduced expression of these proteins has been shown by IHC in high grade metastatic breast carcinoma. Here we report the molecular characterization of this repression. Highly invasive breast cancer cells (MDA-MB-231 and BT-549) express high levels of SNAI2 while mildly invasive (MCF 7 and MDA-MB-468) cells do not express SNAI2. Over-expression of SNAI2 in the SNAI2-negative MCF7 and MDA-MB-468 cells down regulated the mRNA and protein levels of the catenins in these cells. siRNA-mediated knock down of SNAI2 in the SNAI2-positive MDA-MB-231 and BT549 cells elevated the mRNA and protein levels of these proteins in these cells. SNAI2 over-expression induces the invasion and migration in non invasive cells, while down-regulation of the SNAI2 decreases the invasion and migration potential of highly invasive breast cancer cells. Chromatin immunoprecipitation data revealed co-recruitment of CtBP1 and HDAC1 at the catenin gene promoters in the SNAI2-expressing cells further indicating that SNAI2 represses these genes through chromatin remodeling. Our study thus adds to the mode of action of SNAI2 in mediating metastatic conversion of human breast cancer cells. Supported by the DOD-CDMRP IDEA Grant# W81XWH-06-1-0466 and the Susan G. Komen Breast Cancer Foundation grant# BCTR0707627 to GC. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr LB-22.
Prolonged confusional state and EEG seizure activity following concurrent ECT and lithium use
Authors: R D Weiner, A D Whanger, C W Erwin, W P Wilson
Journal: American Journal of Psychiatry (1980)

In the recent APA survey on ebectroconvulsive therapy (ECT), only 20% of the psychiatrist respondents felt that lithium carbonate and ECT were incompatible (1). At the same time, however, there is growing evidence (2-6) that this combination may be associated with the development of a severe acute organic brain syndrome, even in patients who tolerate either treatment well when it is given separately. Although only Ray (3) and Small and associates (6) have reported the occurrence of seizure activity as a part of such a syndrome (3, 6), the common presentation of waxing and waning disorientation and confusion is similar to certam types of seizure manifestations. Therefore, we present here a case in which the patient’s EEG showed evidence of status epilepticus while at the same time the patient was in a fluctuating confusional state. Case Report
Abstract 649: Mirk/dyrk1B kinase inactivation increases gemcitabine efficacy towards quiescent pancreatic cancer cells
Authors: Daina Z. Ewton, Maria Vilenchik, Ann Polonskaia, Ann Hoffman, Karen Zipf, John F. Boylan, Dave Heimbrook, Jing Hu, Eileen A. Friedman
Journal: Cancer Research (2011)

Abstract A major problem in the treatment of cancer is the presence of residual quiescent cancer cells that are relatively insensitive to most chemotherapeutic drugs and radiation. Such cancer cells are believed to cause tumor recurrence when they re-enter the cell cycle under favorable conditions of the microenvironment. Gemcitabine is the drug most often used for treatment of pancreatic cancer, but the response rate is less than 20%. Since stratagems to increase delivery of gemcitabine by inhibiting stromal hedgehog signaling have shown some success, identifying methods to increase gemcitabine efficacy is timely. The serine/threonine kinase Mirk/dyrk1B is expressed at very low levels in most normal tissues, but is overexpressed or amplified in most pancreatic cancers. Mirk maintains pancreatic cancer cells in a viable quiescent state through its transcriptional co-activator functions for a set of antioxidant proteins that decrease intracellular levels of reactive oxygen species (Cancer Res 2009;69:3317-24). We now show that Panc1 and SU86.86 pancreatic cancer cells undergo a reversible quiescent arrest in G0 through activation of Chk2 and autophagy to reduce ribosomal RNA levels, with little apoptosis or senescence. Depletion of Mirk/dyrk1B by either induced shRNA or transfected RNAi duplexes or inhibition of Mirk's kinase activity by a small molecule inhibitor increased DNA damage in quiescent pancreatic cancer cells, either grown attached to petri dishes or in small clumps in suspension as a model for ascites. DNA damage was detected by increased phosphorylation of the histone protein H2AX and by an increase in S phase checkpoints after the quiescent cells re-entered cycle in response to serum mitogens. Pharmacological inhibition of Mirk kinase induced a dose-dependent cleavage of the apoptotic marker proteins PARP and caspase 3, reduced Akt activation, and led to cleavage of the autophagic marker protein LC3. Pretreatment with the Mirk kinase inhibitor increased tumor cell kill 5-fold by short exposures to marginally toxic gemcitabine concentrations. In prior studies Mirk depletion had no detectable effect on the viability of normal diploid fibroblasts (Cancer Res 2007;67:7247-55), while other investigators have shown that embryonic knockout was not lethal (Leder et al, Biochem J 2003;372:881-8). Thus the small molecule Mirk/dyrk1B kinase inhibitor sensitized pancreatic cancer cells to low gemcitabine concentrations, while knockout or depletion of Mirk/dyrk1B had no detectable effect on normal tissue. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 649. doi:10.1158/1538-7445.AM2011-649
Studies Conflict on Fire Fighters' Risk of Cancer
Authors: F. X. Mahaney
Journal: JNCI Journal of the National Cancer Institute (1991)

Journal Article Studies Conflict on Fire Fighters' Risk of Cancer Get access Francis X. Mahaney, Jr. Francis X. Mahaney, Jr. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 83, Issue 13, 3 July 1991, Pages 908–909, https://doi.org/10.1093/jnci/83.13.908 Published: 03 July 1991
DIAGNÓSTICO PRECOZ DE LESIONES POR EL VIRUS DEL PAPILOMA HUMANO (VPH) EN VARONES VIH+ QUE PRACTICAN SEXO ANAL CON HOMBRES: PAPEL DE LA RECTOSCOPIA Y EXPERIENCIA EN NUESTRO HOSPITAL
Authors: C González-Artacho, P De la Torre Rubio, AM Matas Cobos, M López de Hierro Ruíz, C Gil Anguita, C Hidalgo Tenorio, M Rivero Rodríguez, J De Teresa Galván
Journal: Endoscopy (2012)

Introducción: El VPH puede causar displasia y cáncer anal. En pacientes VIH+ las lesiones por VPH son más agresivas, siendo conveniente plantear algún tipo de vigilancia. Objetivo: Analizar el papel de la endoscopia en el diagnóstico precoz de lesiones por VPH en varones VIH+. Material y método: Revisamos las anorectoscopias realizadas con endoscopio flexible desde 2009 a varones VIH+ que tenían sexo anal con hombres, en un programa de despistaje de lesiones displásicas y colonización por VPH de mucosa anal. Las lesiones de bajo grado (LSIL) con genotipos de riesgo elevado o lesiones de alto grado (HSIL) en la citología anal a ciegas se sometieron a rectoscopia/anuscopia con instilación de ácido acético, toma de citología y biopsias. Elaboramos un estudio descriptivo retrospectivo. Resultados: Revisamos 55 individuos. De edad media 37±8 años y tiempo medio desde el diagnóstico de VIH+ 56 meses. El 23.6% presentaba infección por genotipos de VPH de bajo riesgo, 29.1% de alto riesgo, y 38.2% ambos. Endoscópicamente no se encontraron hallazgos en 49.1%, 40.1% lesiones papilomatosas verrugosas anales, 7.3% condilomas evidentes, y 1.8% lesión polipoidea. La citología resultó negativa en el 32.8%; LSIL en 23.6% de los cuales la mitad no presentaban alteraciones endoscópicas; y HSIL en 15 (27.3%), de ellos 6 con endoscopia normal. Las biopsias fueron normales en el 25.5%, con lesión intraepitelial anal grado I (AIN I) en 41.9% (23 pacientes) de los cuales 11 no presentaban hallazgos macroscópicos; AIN II en 17.2% (7), de ellos 2 con endoscopia normal; AIN III en 9.1% (5) y carcinoma in situ 3.6% (2 casos). Todos los AIN III y carcinoma in situ presentaban lesiones en la anorectoscopias Existió correlación histológica de la pieza quirúrgica en 12 de los 14 casos (85.7%) remitidos para cirugía (AIN II, AIN III y carcinoma in situ). Conclusiones: -Es necesario el seguimiento de pacientes VIH+ infectados por VPH para la detección precoz de lesiones premalignas o malignas.-Para seguimiento y diagnóstico de lesiones de alto grado de malignidad en la mucosa del canal anal de pacientes VIH+ y VPH, la citología realizada mediante rectoscopia tiene una baja rentabilidad.-La histología mediante rectoscopia constituye la prueba de elección, por lo que podría estudiarse como método de cribado de estas lesiones.-En pacientes VIH+ puede observarse displasia y evidencia histológica de VPH en ausencia de lesiones endoscópicas.
THE PREDICTOR OF CORONARY VASOSPASM IN THE WOMEN PATIENTS WITH CHEST PAIN: FROM THE KOREAN WOMEN’S CHEST PAIN REGISTRY (KOROSE) STUDY
Authors: Sang Min Park, Kyung-Soon Hong, Wan Joo Shim, Seong-Mi Park, Sua Kim, Min-Na Kim, Youn Hyun Kim, Na Jin Oh, Mi Seung Shin, Myung-A Kim, Yong-Jin Kim, Hyun Ju Yoon, Gil Ja Shin, Yoon-Kyung Cho, Sung-Eun Kim, Kyoung Im Cho
Journal: Journal of the American College of Cardiology (2015)
ASSOCIATION OF CHANGES IN HEMODYNAMIC INDICES OF CONTRACTILE FUNCTION WITH CLINICAL OUTCOMES DURING TREATMENT OF ACUTE DECOMPENSATED HEART FAILURE
Authors: Eliany Mejia Lopez, Kenneth Bilchick, James Bergin, Jose Tallaj, Jamie Kennedy, Mohammad Abuannadi, Pamela C. Kimeto, Sula Mazimba
Journal: Journal of the American College of Cardiology (2016)
Abstract 5011: Difference in expression of STAT3 and STAT5b in Swedish and Egyptian patients with activated b-cell subtype of diffuse large b-cell lymphoma
Authors: Therese Jacobson, Abeer A. Bahnassy, Joachim Lundahl, Katja Prokovskaja Tamm, Anna Porwit, Abdel-Rahman N. Zekri, Hussein M. Khaled, Håkan Mellstedt, Ali Moshfegh
Journal: Cancer Research (2011)

Abstract Diffuse Large B-cell lymphoma (DLBCL), the most common type of lymphoma in adults, accounts for approximately 30 to 40% of newly diagnosed lymphomas. Using gene expression profiling, DLBCL can be divided into three immunologically indistinguishable subtypes: the germinal center B-cell like (GBC), the activated B-cell like (ABC) and the primary mediastinal B-cell lymphoma (PMBL) subtype. The aim of the study was to compare gene expression profiles of Swedish and Egyptian ABC DLBCL patients. Formalin fixed and paraffin embedded material of 67 Egyptian and 15 Swedish ABC DLBCL patients were used in the study. Affymetrix gene expression platform was used for profiling and the analysis was carried out using GeneSpring GX software. Quantitative PCR (qPCR) and confocal microscopy was used to verify the findings. The GeneSpring GX analysis showed that 3247 genes were at least 2 fold up- or downregulated comparing the two patient groups. Among these were 1827 genes upregulated and 1420 genes downregulated. Gene expression analysis was verified using qPCR showing that STAT3 was upregulated with a fold change of 3.1 in the Swedish patients and that STAT5b was upregulated with a fold change of 1.3 in the Egyptian patients. Confocal microscopy showed protein activity of STAT3 and 5b in the nucleus of Swedish and Egyptian patients respectively using monoclonal antibodies. This is the first study that reveals diversity in expression of STATs in different populations of ABC DLBCL patients. STAT3 and 5b are known to have different pathways of activation and targeted disruption has shown their functional differences. Using gene expression profiling, we revealed different expression levels of STAT3 and STAT5b in Swedish and Egyptian ABC DLBCL patients. Since the populations of Sweden and Egypt are exposed to different infectious agents, the results of the present study further raise the question concerning viral etiology in ABC-DLBCL possibly due to repeated infections and chronic inflammation. In general, these findings give additional evidence to the importance of signaling pathways involving STATs in ABC DLBCL. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 5011. doi:10.1158/1538-7445.AM2011-5011
Predominant T<sub>H2</sub>-like Bronchoalveolar T-Lymphocyte Population in Atopic Asthma
Authors: Douglas S. Robinson, Qutayba Hamid, Sun Ying, Anne Tsicopoulos, Julia Barkans, Andrew M. Bentley, Christopher Corrigan, Stephen R. Durham, A. Barry Kay
Journal: New England Journal of Medicine (1992)

In atopic asthma, activated T helper lymphocytes are present in bronchial-biopsy specimens and bronchoalveolar-lavage (BAL) fluid, and their production of cytokines may be important in the pathogenesis of this disorder. Different patterns of cytokine release are characteristic of certain subgroups of T helper cells, termed TH1 and TH2, the former mediating delayed-type hypersensitivity and the latter mediating IgE synthesis and eosinophilia. The pattern of cytokine production in atopic asthma is unknown.
FRI0060 Trends in baseline disease activity, response and remission rates in rheumatoid arthritis (RA) during the last decade: Results from the nor-DMARD register:
Authors: A.-B. Aga, E. Lie, K.M. Fagerli, T. Uhlig, T.K. Kvien, E.A. Haavardsholm
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> During the past decade there has been an increasing focus on early, aggressive treatment, and combined with the availability of biologicals this will likely lead to improved outcomes in patients (pts) with RA. Observational data reflect everyday clinical practice and can provide information about implementation of current treatment recommendations. <h3>Objectives</h3> To investigate whether baseline disease activity levels and responses in pts with RA changed during the period 2001-2010. <h3>Methods</h3> Data for this study were provided by the NOR-DMARD register. Adult pts with inflammatory arthropathies starting a new DMARD at five Norwegian rheumatology departments are consecutively included and followed longitudinally. For these analyses methotrexate (MTX) naïve RA pts starting MTX monotherapy (MTX mono), and biological naïve RA pts starting TNFi + MTX (TNFi+MTX) were included. For the descriptive analyses each group was stratified into two-year intervals according to start date. Time trends in several baseline variables were assessed by linear regression analysis with time as the independent variable (continuous 1-10) and the respective baseline variables as dependent variables. CRP, ESR, joint counts and MHAQ were normalised for the linear regression analyses. EULAR good response and DAS28 remission were similarly assessed by logistic regression analysis. <h3>Results</h3> A total of 2573 pts (MTX mono n=1866, TNFi+MTX n=707) were included [70% female, 64% RF+, mean (SD) age 55.0 (13.7) years, disease duration 5.1 (8.5) years]. Significant time trends were found in both groups for baseline values of DAS28, 28-SJC and CRP (table). Significant time trends were found for baseline disease duration, SDAI, MHAQ, 28 TJC, ESR, physician global, patient global and joint pain VAS (data not shown). There was also a time trend showing increasing DAS28 remission rates at 6 months in both groups, whereas a time trend for increasing rates of EULAR good response was only observed for the MTX mono group (table). <h3>Conclusions</h3> These data show that the mean baseline disease activity level when starting MTX treatment and the first TNFi have decreased from high to moderate disease activity. Disease duration when initiating treatment has also decreased significantly. This indicates that clinicians have implemented modern, more aggressive RA treatment strategies which will hopefully result in better long-term patient outcomes. <h3>Disclosure of Interest</h3> A.-B. Aga Consultant for: UCB, E. Lie: None Declared, K. Fagerli: None Declared, T. Uhlig: None Declared, T. Kvien: None Declared, E. Haavardsholm: None Declared